Arcus Biosciences [RCUS] vs Alnylam [ALNY] Detailed Stock Comparison
Arcus Biosciences
NYSE
Loading...
Alnylam
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Arcus Biosciences wins in 5 metrics, Alnylam wins in 12 metrics, with 0 ties. Alnylam appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Arcus Biosciences | Alnylam | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.67 | -213.71 | Alnylam |
| Price-to-Book Ratio | 2.23 | 244.95 | Arcus Biosciences |
| Debt-to-Equity Ratio | 23.68 | 1,093.31 | Arcus Biosciences |
| PEG Ratio | 0.04 | -384.08 | Alnylam |
| EV/EBITDA | -1.36 | -496.41 | Alnylam |
| Profit Margin (TTM) | -113.74% | -12.96% | Alnylam |
| Operating Margin (TTM) | -5.00% | -2.09% | Alnylam |
| Return on Equity | -50.34% | -257.83% | Arcus Biosciences |
| Return on Assets (TTM) | -18.69% | -2.63% | Alnylam |
| Free Cash Flow (TTM) | $-176.00M | $-42.59M | Alnylam |
| 1-Year Return | -35.82% | 75.61% | Alnylam |
| Price-to-Sales Ratio (TTM) | 4.68 | 24.95 | Arcus Biosciences |
| Enterprise Value | $445.08M | $61.40B | Alnylam |
| EV/Revenue Ratio | 1.70 | 24.94 | Arcus Biosciences |
| Gross Profit Margin (TTM) | N/A | 81.52% | N/A |
| Revenue per Share (TTM) | $3 | $19 | Alnylam |
| Earnings per Share (Diluted) | $-3.14 | $-2.49 | Alnylam |
| Beta (Stock Volatility) | 0.83 | 0.32 | Alnylam |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Arcus Biosciences vs Alnylam Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Arcus Biosciences | 0.17% | -5.50% | 19.13% | 23.21% | 18.76% | -23.86% |
| Alnylam | -0.57% | 3.07% | 8.36% | 52.92% | 92.18% | 99.42% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Arcus Biosciences | -35.82% | -55.56% | -47.49% | -34.55% | -34.55% | -34.55% |
| Alnylam | 75.61% | 118.70% | 252.21% | 331.92% | 3,117.06% | 3,386.75% |
News Based Sentiment: Arcus Biosciences vs Alnylam
Arcus Biosciences
News based Sentiment: POSITIVE
Arcus Biosciences delivered exceptional Q2 results, exceeding expectations significantly, and continues to advance its clinical programs with promising data. While insider selling and trading volatility exist, the overall narrative is positive, supported by analyst confidence and upcoming catalysts.
Alnylam
News based Sentiment: POSITIVE
September was a remarkably positive month for Alnylam, driven by the successful launch of Ambutra, strong financial results, and positive analyst revisions. The company's transition to profitability and proactive financial planning further strengthen its investment case, indicating a solid growth trajectory and increasing investor confidence.
Performance & Financial Health Analysis: Arcus Biosciences vs Alnylam
| Metric | RCUS | ALNY |
|---|---|---|
| Market Information | ||
| Market Cap | $1.23B | $61.07B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 863,370 | 1,215,328 |
| 90 Day Avg. Volume | 794,177 | 1,321,166 |
| Last Close | $11.52 | $465.89 |
| 52 Week Range | $6.50 - $18.98 | $205.87 - $484.21 |
| % from 52W High | -39.30% | -3.78% |
| All-Time High | $49.10 (Nov 22, 2021) | $484.21 (Sep 09, 2025) |
| % from All-Time High | -76.54% | -3.78% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 3.10% | 0.17% |
| Quarterly Earnings Growth | 3.10% | 0.17% |
| Financial Health | ||
| Profit Margin (TTM) | -1.14% | -0.13% |
| Operating Margin (TTM) | -0.05% | -0.02% |
| Return on Equity (TTM) | -0.50% | -2.58% |
| Debt to Equity (MRQ) | 23.68 | 1,093.31 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $5.16 | $1.91 |
| Cash per Share (MRQ) | $8.56 | $21.80 |
| Operating Cash Flow (TTM) | $-339,000,000 | $-15,539,000 |
| Levered Free Cash Flow (TTM) | $-113,000,000 | $85.71M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Arcus Biosciences vs Alnylam
| Metric | RCUS | ALNY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.67 | -213.71 |
| Forward P/E | -2.47 | -384.08 |
| PEG Ratio | 0.04 | -384.08 |
| Price to Sales (TTM) | 4.68 | 24.95 |
| Price to Book (MRQ) | 2.23 | 244.95 |
| Market Capitalization | ||
| Market Capitalization | $1.23B | $61.07B |
| Enterprise Value | $445.08M | $61.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.70 | 24.94 |
| Enterprise to EBITDA | -1.36 | -496.41 |
| Risk & Other Metrics | ||
| Beta | 0.83 | 0.32 |
| Book Value per Share (MRQ) | $5.16 | $1.91 |
Financial Statements Comparison: Arcus Biosciences vs Alnylam
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RCUS | ALNY |
|---|---|---|
| Revenue/Sales | $28.00M | $773.69M |
| Cost of Goods Sold | N/A | $142.95M |
| Gross Profit | N/A | $630.74M |
| Research & Development | $122.00M | $323.62M |
| Operating Income (EBIT) | $-122.00M | $-16.20M |
| EBITDA | $-108.00M | $35.44M |
| Pre-Tax Income | $-112.00M | $-35.36M |
| Income Tax | $0 | $30.92M |
| Net Income (Profit) | $-112.00M | $-66.28M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RCUS | ALNY |
|---|---|---|
| Cash & Equivalents | $192.00M | $1.02B |
| Total Current Assets | $1.03B | $3.27B |
| Total Current Liabilities | $192.00M | $1.08B |
| Long-Term Debt | $48.00M | $1.26B |
| Total Shareholders Equity | $531.00M | $115.44M |
| Retained Earnings | $-1.24B | $-7.35B |
| Property, Plant & Equipment | N/A | $695.92M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RCUS | ALNY |
|---|---|---|
| Operating Cash Flow | $-128.00M | $-145.39M |
| Capital Expenditures | $-1.00M | $-8.97M |
| Free Cash Flow | $-133.00M | $-127.28M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | RCUS | ALNY |
|---|---|---|
| Shares Short | 9.83M | 3.97M |
| Short Ratio | 13.27 | 2.99 |
| Short % of Float | 0.14% | 0.04% |
| Average Daily Volume (10 Day) | 863,370 | 1,215,328 |
| Average Daily Volume (90 Day) | 794,177 | 1,321,166 |
| Shares Outstanding | 92.20M | 129.29M |
| Float Shares | 59.89M | 126.15M |
| % Held by Insiders | 0.35% | 0.04% |
| % Held by Institutions | 0.68% | 0.99% |
Dividend Analysis & Yield Comparison: Arcus Biosciences vs Alnylam
| Metric | RCUS | ALNY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |